Participants will be randomly assigned to empagliflozin or placebo. Participants will take the study medication (empagliflozin or placebo) for 12 weeks.More
- Patients with chronic HF diagnosed for at least 3 months before Visit 1 and currently in NYHA class II-IV - Chronic HF with reduced EF defined as LVEF ≤ 40 % as per echocardiography at Visit 1  - Elevated NT-proBNP > 450 pg/ml for patients without atrial fibrillation (AF) OR > 600 pg/ml for patients with AF - Patients must be clinically stable and on appropriate and stable dose of medical therapy for HF - Clinically stable at randomization with no signs of heart failure decompensation
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
University of Colorado Hospital
Neda Rasouli, MD
Protocol Number: 18-0926
More information available at ClinicalTrials.gov: NCT03448419
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers